Australia's CSL to start work on immunoglobulin product to treat Covid-19

[BENGALURU] Australian biotech firm CSL Ltd said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of Covid-19, the disease caused by the novel coronavirus.

The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from Covid-19, CSL said in a statement on its website.

CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.

REUTERS